A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

Solange Peters, Sarah Danson, Baktiar Hasan, Urania Dafni, Niels Reinmuth, Margarita Majem, Kurt G. Tournoy, Michael Mark, Miklos Pless, Manuel Cobo, Delvys Rodríguez‐Abreu, L. Falchero, Teresa Morán, Ana Laura Ortega Granados, I. Monnet, Katja Mohorčič, B. Massuti Sureda, Daniel Betticher, Ingel Demedts, José Macías, Sinéad Cuffe, Andrea Luciani, José García Sánchez, Alessandra Curioni‐Fontecedro, Oliver Gautschi, Gillian Price, Linda Coate, Roger von Moos, Christoph Zielinski, Mariano Provencio, Jessica Menis, Barbara Ruepp, Alessia Pochesci, Heidi Roschitzki‐Voser, Benjamin Besse, Manuela Rabaglio, Mary O’Brien, Rolf A. Stahel